search
Back to results

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder

Primary Purpose

Osteoarthritis

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
[StroMed + platelet rich plasma (PRP)]
Sponsored by
VivaTech International, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
  2. Patients range from 18-90 years of age.
  3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
  4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
  5. Patients with adequate cardiac and respiratory function.
  6. Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT
  7. Patients must have adequate immune system function, with no known immunodeficiency disease.
  8. Greater than 6 months shoulder pain with the index side (left or right shoulder).

Exclusion Criteria:

  1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
  2. Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke)..
  3. Diagnosis of a transient ischemic attack in the 6 months prior to screening.
  4. Patients infected with hepatitis B, C or HIV.
  5. Patients with Body Mass Index (BMI) > 40kg/m2
  6. Presence of active infection.
  7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
  8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:

    1. Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis
    2. Corticosteroid injection at treatment site within 1 month
    3. Consistent use of NSAIDs within 48 hours of procedure.

Sites / Locations

  • VivaTech International, Inc.Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

StroMed + platelet rich plasma (PRP)

Arm Description

Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.

Outcomes

Primary Outcome Measures

Change is being assessed for the DASH Survey (Disabilities of the Arm, Shoulder, Hand
Disabilities of the Arm, Shoulder, and Hand

Secondary Outcome Measures

Change is being assessed by MRI of afflicted joint
Looking for cartilage regrowth via MRI
Change is being assessed for the SPADI Survey (Shoulder Pain and Disability Index)
Shoulder Pain and Disability Index
Change is being assessed for the SF36 Survey (Short Form Health Survey)
Short Form Health Survey
Change is being assessed for the NRS Survey (Numerical Rating Scale for Pain)
Numerical Rating Scale for Pain

Full Information

First Posted
July 8, 2016
Last Updated
August 4, 2023
Sponsor
VivaTech International, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02844738
Brief Title
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
Official Title
Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Shoulder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 2015 (undefined)
Primary Completion Date
August 2025 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VivaTech International, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the shoulder. Follow-up will consist of a larger sample including 4,000 patients.
Detailed Description
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the shoulder. Follow-up will consist of a larger sample including 4,000 patients. Patients will be treated for Osteoarthritis (OA) of the shoulder due to degeneration or chronic injury. They will be treated with autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints. Patient outcomes will be tracked with laboratory tests for inflammation markers, the DASH and SPADI questionnaires and a follow up MRI at various endpoints to 6 months. SF-36 forms (a quality of life measure) and numerical ratings scales (NRS) will also be used to assess safety and efficacy of treatment, as well as any reduction in patient medication and/or delay in pending shoulder planning/replacement therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
StroMed + platelet rich plasma (PRP)
Arm Type
Experimental
Arm Description
Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
Intervention Type
Biological
Intervention Name(s)
[StroMed + platelet rich plasma (PRP)]
Intervention Description
Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
Primary Outcome Measure Information:
Title
Change is being assessed for the DASH Survey (Disabilities of the Arm, Shoulder, Hand
Description
Disabilities of the Arm, Shoulder, and Hand
Time Frame
0,2,6 months
Secondary Outcome Measure Information:
Title
Change is being assessed by MRI of afflicted joint
Description
Looking for cartilage regrowth via MRI
Time Frame
0 and (6 months optional)
Title
Change is being assessed for the SPADI Survey (Shoulder Pain and Disability Index)
Description
Shoulder Pain and Disability Index
Time Frame
0,2,6 Months
Title
Change is being assessed for the SF36 Survey (Short Form Health Survey)
Description
Short Form Health Survey
Time Frame
0,2,6 Months
Title
Change is being assessed for the NRS Survey (Numerical Rating Scale for Pain)
Description
Numerical Rating Scale for Pain
Time Frame
0,2,6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury. Patients range from 18-90 years of age. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl. Patients with adequate cardiac and respiratory function. Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT Patients must have adequate immune system function, with no known immunodeficiency disease. Greater than 6 months shoulder pain with the index side (left or right shoulder). Exclusion Criteria: Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke).. Diagnosis of a transient ischemic attack in the 6 months prior to screening. Patients infected with hepatitis B, C or HIV. Patients with Body Mass Index (BMI) > 40kg/m2 Presence of active infection. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to: Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than shoulder osteoarthritis Corticosteroid injection at treatment site within 1 month Consistent use of NSAIDs within 48 hours of procedure.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Scott M Herkes, MBA
Phone
855-984-8287
Email
scott.herkes@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Michael P Hutchinson, DVM
Phone
412-503-3788
Email
drmike@vivatechusa.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark LoDico, MD
Organizational Affiliation
Advanced Regenerative Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
VivaTech International, Inc.
City
Grove City
State/Province
Pennsylvania
ZIP/Postal Code
16127
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott M Herkes, MBA
Phone
855-984-8287
Email
scott.herkes@gmail.com
First Name & Middle Initial & Last Name & Degree
Michael Hutchinson, DVM
Phone
412-503-3788
Email
drmike@vivatechusa.com
First Name & Middle Initial & Last Name & Degree
Mark LoDico, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
VivaTech will monitor data and decide if/when data can be shared
Links:
URL
http://www.vivatechusa.com
Description
Company Website

Learn more about this trial

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder

We'll reach out to this number within 24 hrs